BioMarin's roots are in enzyme replacement therapies for ultra-rare diseases, where there may only be a few thousand patients globally, but strong pricing power and high barriers to entry ...

In practical terms, that means no new clinical trial programmes, although BioMarin said it will continue to support patients who have already been enrolled in studies, and no new launches in other ...

That means that the risk of a patient having to return to Factor VIII replacement is covered by a direct BioMarin financial commitment – akin to a warranty – in return for "substantial and ...

In the fourth quarter, BioMarin's growth was driven by Voxzogo, with a 42% rise in quarterly revenue year over year, contributing $208 million this quarter. Government orders and new patient ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

helping a lot of patients, we feel that we can improve on them,” Friberg said. In achondroplasia, for example, BMN 333 recently began dosing for a first-in-human study, according to BioMarin's ...

Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions. In the quarter, revenues from BioMarin's Enzyme Therapies increased 9% ...

BioMarin Pharmaceutical BMRN reported fourth ... up 14% year over year, driven by increased patient uptake in the United States. The drug’s sales beat the Zacks Consensus Estimate of $94 million ...

In markets with significant expansion potential, we are leveraging BioMarin's robust global footprint and commercial infrastructure to drive awareness and adoption in the eligible patient population.